1420 companies · 1441 sector slots · 20 sectors · 29 below Rs1000cr and not scanned · long-term lens
Trend Spotlight
RBI raises the repo rate 25bps to 5.50% on Oct 7 -- its first hike since Feb 2023 -- and shifts its stance to 'calibrated tightening'.
The MPC's unanimous move came with a raised FY27 CPI projection (5.2%) and a raised FY27 GDP growth projection (7.1%, up from 6.7%), with the RBI citing elevated crude, geopolitical tensions, firm global bond yields and renewed domestic food-price pressure. Governor Malhotra ruled out a near-term cut, leaving the next move as another hike or a pause -- a genuine tightening cross-current against any sector news flipping to ACCUMULATE on price dispersion alone, and a headwind for rate-sensitive financing costs (auto, realty, NBFCs).
▲ 1649 advancing■ 30 unchanged▼ 993 decliningof 2672 equities, vs the 2026-10-08 close
Cash market, ₹ crore
FII / FPI net
▼ -3,568.90
bought 10,374 · sold 13,943
DII net
▲ +4,743.26
bought 15,627 · sold 10,883
FII / FPI
DII
Source: NSE ind_close_all_20261009
(levels, index P/E and P/B) and the full-market bhavcopy (breadth).
Index P/E from NSE's official daily index file.
Sector performance
This session's index move, next to the desk's standing stance. The stance
is a valuation-and-quality reading over years — it does not move because an index had
a good day. Sectors with no listed NSE index show — for the session columns; the stance still applies.
Set aside as undetermined: MOLDTKPAC (▼ -49.95%). A move this
large over one session is usually a bonus, split or demerger rather than a price
change, and a close-only series cannot tell the two apart — so it is neither listed
as a mover nor quietly dropped.
Calls this session
A change to anything but AVOID publishes only after two consecutive
sessions say the same thing; AVOID publishes at once.
Supreme Court recalls its own Rs4,655cr Singampatti lease-rent observation against Bombay Burmah FMCG
The Supreme Court's Aug 19 order recalled a paragraph from its own May 29 order that had been read as endorsing a Rs4,655cr lease-rent figure against BBTC, on the grounds BBTC was never served formal notice or given a hearing on the merits. This is not a resolution of the underlying dispute -- no demand has been formally raised, no provision disclosed, and the question of what, if anything, BBTC owes remains open -- but it removes the specific adverse judicial finding that had been read as backing the headline number. The stock rose over 12% on the news.
Vadilal Industries' related-party supply pact (79% of FY26 revenue) lapses Oct 1, awaits Oct 27 shareholder vote FMCG
Vadilal Industries' 10-year supply agreement with related party Vadilal Enterprises -- which accounted for 79% of FY26 revenue -- expired Sept 30 and could not be renewed Oct 1 for lack of the required public-shareholder approval under SEBI's related-party rules. A revised 12-month version has been negotiated but needs approval at an EGM on Oct 27 (record date Oct 20), leaving a gap where the bulk of the company's revenue runs without a formal contract. India Ratings separately placed Vadilal's bank-loan facilities on negative watch on Sept 23. This is directly relevant to the pending BUY->HOLD call given the revenue concentration and the known family dispute behind it.
Zen Technologies' order book still short of its ~Rs2,500cr FY27 target; Q1 profit fell 27.8% YoY Capital Goods
The most recent confirmed figures -- Q1 FY27's Rs1,239cr consolidated order book plus a Rs177.5cr simulator order added in July -- put Zen Technologies well short of the ~Rs2,500cr target management has guided toward, with Q1 net profit down 27.8% YoY to Rs34.46cr. A separately reported Rs404cr MoD order (anti-drone/C-UAS plus simulators) is covered by sources that disagree on timing (Jan vs Apr 2026), so it's unclear whether it's additive to the Rs1,239cr figure. This neither confirms nor falsifies the order-book ramp thesis behind the pending BUY->QUALITY-WAIT downgrade -- the book is growing toward the target but isn't there yet, and the profit decline is a mild headwind against the bullish narrative.
Shukra Pharmaceuticals' nine new unrelated subsidiaries still show near-zero revenue in FY26 Pharmaceuticals
Sources disagree on scale -- FY26 consolidated financials list four new subsidiaries (medtech, robotics, woundcare, diabetes tech) while press coverage describes nine incorporated entities including defence/aerospace -- but FY26 consolidated revenue was only ~Rs5,673 lakh and the medtech segment specifically reported zero revenue, with the flagged Rs600cr Greater Noida facility appearing in only one unconfirmed source. This neither confirms disciplined execution nor evidences cost overruns on the open governance-risk claim around Shukra's rapid diversification; the subsidiaries are too new and revenue-less to judge either way.
Entry score is 40% cheap-vs-history + 25% quality trend + 20% news catalyst + 15% technicals, for the 4 sectors with a researched catalyst. The other 16 show —: no catalyst was researched for them, so their score renormalises over the remaining three inputs rather than assuming a neutral headline. ≥62 accumulate · 45–61 watch · <45 avoid.
Source: data/verdicts.json × NSE sector index closes.
Stocks to Watch
Split evenly across large/mid/small/micro cap so this list isn't one
tier's picks — new calls first, then the highest long-term composites within each.
Micro-cap names are boxed and flagged Highly Volatile — worth
watching, not a call to buy — since their price swings run about twice every other
tier's. Each card shows the figures that selected it — open the desk for the full
six-lens panel.
P/E in the 89th percentile of its own 3-year range · ROCE 14.6% (up 10.6pt over 5y) · Piotroski 7/9
Composite 61.8Mkt Cap 4,960 cr · MicroP/E 42.74ROCE 14.6%Piotroski 7/9
Lens Weights Recalibrated
Every Sunday, each lens's weight is re-tilted from its prior on
all evidence to date of whether its ratings predicted subsequent returns, measured
separately within each cap tier (data/lens_ic.json). Thin evidence moves a weight
a little, a consistent edge more -- see METHODOLOGY.md. Every past change stays
on the record in data/lens_weight_changes.json.
Tier
Lens
Weight
t-stat
Hit rate
Weeks measured
Large
Quality
1.4091 → 1.3442
-0.4216
59%
8.2
Large
Financial Health
1.979 → 1.91
1.2273
63%
8.2
Large
Value
1.1404 → 1.0512
-0.5066
56%
8.2
Large
Earnings Quality
1.2998 → 1.3139
1.4757
71%
8.2
Large
Growth Outlook
0.861 → 0.7981
-0.0097
59%
4.4
Large
Momentum
0.6138 → 0.6029
0.8754
68%
8.2
Mid
Quality
1.3032 → 1.3663
-0.3604
54%
8.2
Mid
Financial Health
1.8378 → 1.9321
1.3132
66%
8.2
Mid
Value
1.113 → 1.1381
-0.2071
61%
8.2
Mid
Earnings Quality
0.9049 → 0.9127
-0.353
54%
8.2
Mid
Growth Outlook
0.7399 → 0.5795
-1.2402
86%
1.4
Mid
Momentum
0.6691 → 0.6902
1.9959
76%
8.2
Small
Quality
1.8524 → 1.8341
0.9582
56%
6.4
Small
Financial Health
1.7831 → 1.6513
0.4092
50%
6.4
Small
Value
1.1041 → 1.0405
-0.5447
59%
6.4
Small
Earnings Quality
0.8708 → 0.7647
-1.0215
59%
6.4
Small
Growth Outlook
1.0057 → 0.9895
1.0299
79%
2.8
Small
Momentum
0.6938 → 0.7136
2.5432
78%
6.4
Micro
Quality
1.9052 → 1.9961
1.5909
78%
6.4
Micro
Financial Health
1.7684 → 1.8473
1.0024
62%
6.4
Micro
Value
1.0792 → 1.0396
-0.5478
59%
6.4
Micro
Earnings Quality
1.0287 → 0.9775
-0.0899
53%
6.4
Micro
Growth Outlook
0.7073 → 0.6162
-0.9933
78%
3.6
Micro
Momentum
0.7238 → 0.7275
3.0553
91%
6.4
How We Evaluate
Metric
Why it is in the framework
Source
Return on capital, level and trend
Durable high ROCE predicts future returns; the trend separates a moat from a good year
Novy-Marx 2013 JFE
Gross profitability (GP/assets)
As predictive as book-to-market, and less prone to the value trap
Novy-Marx 2013 JFE
Piotroski F-score
A nine-signal accounting checklist that separates real improvers from statistically cheap traps